Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Overview of annual performance metrics for index funds highlights consistency and risk-adjusted returns to inform choices.
21,807 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Two fast-casual leaders headline the 2026 investor debate: a Mediterranean newcomer with fast expansion and a Mexican...
As lenders chase ROI from AI, a governance-first pivot for mortgage workflows is gaining steam. Banks report better a...
When a MongoDB director sells a sizable block of shares, investors pause to weigh the meaning. This article breaks do...
AppLovin led a week of outsized moves in AI-linked shares, with Tempus AI and Micron following suit as memory and sof...
As 2025 unfolds, investors weigh the promise and pitfalls of ADMA Biologics. This guide breaks down earnings drivers,...
C3.AI has faced a rough run, leaving investors wondering if a comeback is possible. This article breaks down the fact...
Two fintech giants, Robinhood and Coinbase, battle for every investor's screen. This guide breaks down strengths, ris...
Palantir has sparked debate among investors with rapid growth and high expectations. This guide breaks down whether p...
Dive into tomi (tomz) 2025 earnings and the Q4 transcript to understand revenue drivers, margins, and what it means f...
Microsoft stock is moving higher in a volatile market, defying a tech sell-off. This article breaks down the drivers ...
A whispered cornerstone of Warren Buffett's private investing approach is said to lead the pack in a $786 million sec...